ZAI LAB LTD0000006 (1ZLB) - Total Assets
Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) holds total assets worth €1.10 Billion EUR (≈ $1.28 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ZAI LAB LTD0000006 (1ZLB) net asset quality to measure how much of total assets are equity-financed.
ZAI LAB LTD0000006 - Total Assets Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's total assets have evolved over time, based on quarterly financial data. Explore 1ZLB long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
ZAI LAB LTD0000006 - Asset Composition Analysis
Current Asset Composition (December 2025)
ZAI LAB LTD0000006's total assets of €1.10 Billion consist of 86.9% current assets and 13.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 58.0% |
| Accounts Receivable | €106.12 Million | 9.1% |
| Inventory | €74.75 Million | 6.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €79.00 Million | 6.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ZAI LAB LTD0000006 market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ZAI LAB LTD0000006's current assets represent 86.9% of total assets in 2025, a decrease from 93.2% in 2021.
- Cash Position: Cash and equivalents constituted 58.0% of total assets in 2025, down from 59.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 9.1% of total assets.
ZAI LAB LTD0000006 Competitors by Total Assets
Key competitors of ZAI LAB LTD0000006 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
ZAI LAB LTD0000006 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.40 | 3.26 | 3.01 |
| Quick Ratio | 2.19 | 3.09 | 2.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €551.75 Million | €722.06 Million | €574.23 Million |
ZAI LAB LTD0000006 - Advanced Valuation Insights
This section examines the relationship between ZAI LAB LTD0000006's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.23 |
| Latest Market Cap to Assets Ratio | 1.55 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | €1.17 Billion |
| Market Capitalization | $1.82 Billion USD |
Valuation Analysis
Above Book Valuation: The market values ZAI LAB LTD0000006's assets above their book value (1.55x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: ZAI LAB LTD0000006's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual total assets of ZAI LAB LTD0000006 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.17 Billion ≈ $1.37 Billion |
-1.13% |
| 2024-12-31 | €1.19 Billion ≈ $1.39 Billion |
+14.42% |
| 2023-12-31 | €1.04 Billion ≈ $1.21 Billion |
-15.07% |
| 2022-12-31 | €1.22 Billion ≈ $1.43 Billion |
-24.21% |
| 2021-12-31 | €1.61 Billion ≈ $1.88 Billion |
-- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more